Clicky

Santen Pharmaceutica(SNPHF)

Description: Santen Pharmaceutical Co., Ltd. researches and develops, produces, and markets pharmaceuticals and medical devices in Japan and internationally. It offers prescription pharmaceutical products for glaucoma and ocular hypertension, dry eyes, allergic conjunctivitis, severe keratitis with dry eyes, vernal keratoconjunctivitis, uveitis, wet age-related macular degeneration, and myopia; and over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.


Keywords: Medicine Hypertension Macular Degeneration Glaucoma Wet Age Related Macular Degeneration Coma Uveitis Myopia Allergic Conjunctivitis Ocular Hypertension Conjunctivitis Counter Pharmaceutical Products Over The Counter Pharmaceutical Products Prescription Pharmaceutical Products Keratoconjunctivitis Markets Pharmaceuticals Pharmaceuticals And Medical Devices Vernal Santen Pharmaceutical Severe Keratitis Vernal Keratoconjunctivitis

Home Page: www.santen.com

Grand Front Osaka Tower A
Osaka, 530-8552
Japan
Phone: 81 6 7664 8621


Officers

Name Title
Mr. Takeshi Ito President, CEO & Representative Director
Mr. Kazuo Koshiji CFO & Corporate Officer
Ms. Rie Nakajima COO, Corporate Officer & Director
Ms. Kaori Itagaki General Manager of Investor Relations Group
Ms. Mika Masunari General Counsel & Chief Compliance Officer
Ms. Nobuko Kato Chief Communications Officer
Mr. Shinichi Teramachi Corp. Officer, Head of Sales and Head of Japan Sales & Marketing
Mr. Kenji Morishima Corporate Officer & Head of China Product Development Department
Mr. Takahiro Morita Global Head of Core Principle & Sustainability and Corporate Officer
Mr. Frank Binder Corporate Officer & Head of Supply Chain Division

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 13.459
Trailing PE: 21.9375
Price-to-Book MRQ: 1.9257
Price-to-Sales TTM: 0.0128
IPO Date:
Fiscal Year End: March
Full Time Employees: 3744
Back to stocks